Skip to content

The application of APT-CEST imaging technology combined with MR routine scanning in the early diagnosis of ultra-micro breast cancer and the early efficacy evaluation of neoadjuvant chemotherapy for breast cancer

The application of APT-CEST imaging technology combined with MR routine scanning in the early diagnosis of ultra-micro breast cancer and the early efficacy evaluation of neoadjuvant chemotherapy for breast cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036561
Enrollment
Unknown
Registered
2020-08-24
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:The diagnostic criteria, staging criteria and NAC efficacy criteria of breast cancer are based on pathological diagnosis.
Index test:APT-CEST&#32
combined&#32
with&#32

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Female, greater than or equal to 18 years old, clinical first physical examination or other X-ray, ultrasound examination indicated suspicious or confirmed breast nodules or masses can not be determined, require MR physical examination to find ultra-micro breast cancer.Patients receiving neoadjuvant chemotherapy were selected.Informed consent to participate in the project.

Exclusion criteria

Exclusion criteria: Pregnant women; Persons with impaired renal function; Allergic history of gadolinium contrast agent; People with claustrophobia; Patients with a metal implant or pacemaker implanted in the body.

Design outcomes

Primary

MeasureTime frame
sensitivity;specificity;correlation;

Countries

China

Contacts

Public ContactAn Chen

Shanghai General Hospital

annchen88@163.com+86 13651840796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026